Absolute bioavailability of mianserin tablets and solution in healthy humans
- PMID: 3830718
- DOI: 10.1007/BF03189759
Absolute bioavailability of mianserin tablets and solution in healthy humans
Abstract
A pharmacokinetic study with mianserin . HCl was performed in six healthy male subjects. The subjects were treated on different occasions intravenously with a constant-rate infusion of 5 mg mianserin. HCl in 1 h, orally with a single dose of 60 mg as two tablets of 30 mg each and with 60 mg as an oral solution. The wash-out period between treatments was 1 month. Blood samples were taken at predetermined times over a period of 120 h following dosing. The mianserin concentration in the plasma samples was determined and the results were pharmacokinetically analyzed. The intravenous data could be adequately described by a 3-compartment model and the oral data by a 2-compartment model, both with first-order transfer and elimination rate constants. The mean plasma clearance of mianserin was found to be 19 +/- 2 l h-1 (mean +/- SEM), the kinetic volume of distribution 444 +/- 250 l, the steady-state volume of distribution 242 +/- 171 l and the elimination half-life 33 +/- 5 h. The absolute bioavailability in terms of extent of absorption was 22 +/- 3% for the solution and 20 +/- 3% for the tablets. The mean peak level for the solution was 79 +/- 11 ng X ml-1 and for the tablets 54 +/- 5 ng X ml-1; mean peak time for the solution was 1.1 +/- 0.2 h and for the tablets 1.4 +/- 0.2 h. The mean absorption half-life for the solution was 0.43 +/- 0.13 h and for the tablets 0.39 +/- 0.11 h.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
The pharmacokinetics of mianserin.Br J Clin Pharmacol. 1983;15 Suppl 2(Suppl 2):313S-322S. doi: 10.1111/j.1365-2125.1983.tb05880.x. Br J Clin Pharmacol. 1983. PMID: 6824562 Free PMC article.
-
Mianserin kinetics in depressed patients.Clin Pharmacol Ther. 1983 Jun;33(6):757-62. doi: 10.1038/clpt.1983.103. Clin Pharmacol Ther. 1983. PMID: 6851406
-
A pharmacokinetic study of mianserin.Eur J Clin Pharmacol. 1982;21(6):517-20. doi: 10.1007/BF00542048. Eur J Clin Pharmacol. 1982. PMID: 7075657
-
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.Clin Pharmacokinet. 2007;46(9):787-802. doi: 10.2165/00003088-200746090-00006. Clin Pharmacokinet. 2007. PMID: 17713976 Clinical Trial.
-
Cefetamet pivoxil clinical pharmacokinetics.Clin Pharmacokinet. 1993 Sep;25(3):172-88. doi: 10.2165/00003088-199325030-00002. Clin Pharmacokinet. 1993. PMID: 8222459 Review.
Cited by
-
Bioavailability prediction based on molecular structure for a diverse series of drugs.Pharm Res. 2004 Jan;21(1):68-82. doi: 10.1023/b:pham.0000012154.09631.26. Pharm Res. 2004. PMID: 14984260
-
The pharmacokinetics of mianserin suppositories for rectal administration in dogs and healthy volunteers: a pilot study.J Pharm Health Care Sci. 2016 May 17;2:12. doi: 10.1186/s40780-016-0046-7. eCollection 2016. J Pharm Health Care Sci. 2016. PMID: 27190632 Free PMC article.
-
Pharmacokinetic optimisation of therapy with newer antidepressants.Clin Pharmacokinet. 1994 Oct;27(4):307-30. doi: 10.2165/00003088-199427040-00005. Clin Pharmacokinet. 1994. PMID: 7834966 Review.
-
Variability in the elimination of mianserin in elderly patients.Br J Clin Pharmacol. 1989 Apr;27(4):445-51. doi: 10.1111/j.1365-2125.1989.tb05392.x. Br J Clin Pharmacol. 1989. PMID: 2719901 Free PMC article.